Mind Medicine Inc Ordinary Shares (Sub Voting) MNMD 深 沪
等待开盘 10-04 09:30:00 美东时间
12.52
+0.300
+2.45%
华盛通- 最 高12.76
- 今 开12.34
- 成交量 100.83万股
- 最 低 12.0115
- 昨 收 12.22
- 总市值 9.53亿
- 52周最高 12.76
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 4.70
- 委 比 9.81%
- 总股本 7608.79万
- 历史最高 86.55
- 量 比 0.50
- 振 幅 6.13%
- 历史最低 2.20
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedelics-reform/
10-02 23:03
'Massachusetts Lawmakers Approve Bill To Create Psychedelic Therapy Pilot Program' - Marijuana Moment
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/
09-13 00:30
MindMed to Engage in Key September Investor Conferences
Mind Medicine ( ($MNMD) ) just unveiled an update. MindMed has announced its pa...
09-10 04:03
MindMed Issues Inducement Grants to New Employees
Mind Medicine ( ($MNMD) ) has provided an update. MindMed announced the issuanc...
09-10 03:35
Mind Medicine’s Breakthrough in Anxiety Disorder Treatment
Mind Medicine ( ($MNMD) ) has shared an announcement. On September 4, 2025, Min...
09-04 23:47
Mind Medicine Says JAMA Publishes Full Results From Phase 2b Study Of MM120 In 198 Adults With Moderate-To-Severe GAD
The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administration of MM120 across four dose levels, with improvements sustained throughout
09-04 23:07
'U.S. Senate Committee To Hold Hearing On Benefits Of Psychedelics For Military Veterans'- Marijuana Moment
https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/
08-22 02:35
电话会总结 ｜ MindMed(MNMD)2025财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： Mind Medicine (MindMed) 截至2025年6月30日的第二季度财务数据显示，公司持有的现金、现金等价物和投资总额为2.379亿美元。2025年研究与开发（R&D）费用为2980万美元，相较于2024年的1460万美元增加了1520万美元。2025年第二季度的管理与行政（G&A）费用为1110万美元，相较于2024年的980万美元增加了130万美元。</p> <p>• **财务指标变化**： - **现金与投资**：截至2025年6月30日，公司现金、现金等价物和投资总额为2.379亿美元，预
08-12 12:05
Chardan Capital Maintains Buy on Mind Medicine, Maintains $20 Price Target
Chardan Capital analyst Rudy Li maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $20 price target.
08-01 19:36
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
